Lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen, which can cause severe illnesses in humans. Th e most vulnerable are the human foetus and immunosuppressed individuals. Since there is no commercially available enzyme-linked immunosorbent assay (ELISA) for the diagnosis of anti-LCMV antibodies in human sera, we developed a sandwich ELISA method detecting anti-nucleoprotein IgG antibodies, using a specifi c monoclonal anti-nucleoprotein antibody and cells persistently infected with LCMV strain MX as antigen. In the present study we show standardization of this ELISA protocol, determination of its clinical specifi city and sensitivity and its application on 30 clinical samples from multiorgan donors. Comparison of these results to the indirect immunofl uorescence antibody test (IFA) demonstrates that ELISA is more sensitive. Th e developed ELISA assay provides a fast, simple and effi cient tool for the clinical detection of anti-nucleoprotein antibodies in human sera.
Introduction
Lymphocytic choriomeningitis virus, a prototype arenavirus, is a rodent-borne pathogen carried mostly by house mouse (Mus musculus), but it has also been detected in other rodent species, such as hamsters, rats, and guinea pigs. Persistently infected rodents shed the virus in urine, faeces, milk, saliva, and semen (Jamieson et al., 2006) . Humans become infected through the contact with contaminated material or by inhalation of aerosolized viral particles. In immunocompetent adults, infections are mostly asymptomatic or mild, with fl u-like symptoms, but diseases of the CNS, such as aseptic meningitis, can also occur (Barton and Mets, 2001) . In contrast to the self-limited acquired postnatal LCMV infection, prenatal infection leads to an increased risk of spontaneous abortion, severe CNS defects (hydrocephalus, microcephaly), and chorioretinitis of the foetus (Bonthius et al., 2007) . Moreover, recently reported transmissions of LCMV through infected solid organ transplants revealed a risk to immunocompromised individuals. Six clusters of organ transplant-associated LCMV and LCMV-like arenavirus transmissions have been documented in the USA and Australia before April 2013. Of 24 recipients (including kidney, liver, lung, and cornea recipients), 15 died of multisystem organ failure. Survivors of these infections were treated with oral ribavirin and reduction of immunosuppressive therapy. Interestingly, LCMV could not always be detected in donors by RT-PCR or serology testing (Fischer et al., 2006; CDC, 2008; Palacios et al., 2008; MacNeil et al., 2012; Schafer et al., 2014) . Th e most commonly used serological tests for detec-*Corresponding author. E-mail: jana.tomaskova@savba.sk; phone: +421-2-59302439. Abbreviations: Ab = antibody; ELISA = enzyme-linked immunosorbent assay; IFA = indirect immunofl uorescence antibody test; LCMV = lymphocytic choriomeningitis virus; NP = nucleoprotein of LCMV tion of specifi c anti-LCMV IgM or IgG antibodies are ELISA and indirect immunofl uorescence assay (IFA) (OIE, 2006) . Complement fi xation test is insensitive and should not be used (Mets et al., 2000) . PCR can be utilized for the detection of viral RNA in the serum or cerebrospinal fl uid (OIE, 2006) . In terms of congenital infection, several authors have noted that LCMV is an underreported and underdiagnosed teratogen, whose true incidence is not defi ned (Jamieson et al., 2006) . More than 70 cases of children with congenital LCMV infection have been reported worldwide (Barton et al., 2002; Bonthius et al., 2007) . Serological studies indicate that approximately 5% of the human population in the United States has LCMV antibodies (Park et al., 1997a) . In a study from an inland city in Argentina, an overall LCMV seroprevalence was 3.3% (Riera et al., 2005) . A seropositivity rate of 4% was detected among inhabitants of Nova Scotia (Marrie and Saron, 1998) , 1.7% in the Community of Madrid in Spain (Lledó et al., 2003) , 3.5% in the inner city of Birmingham (Park et al., 1997b) . Th e prevalence of LCMV antibodies on the Croatian island of Vir was found to be 36% (detected by IFA) and 13% (by complement fi xation) (Dobec et al., 2006) . Th e study from 1973 proved that 9.1% of the rural population in southern Germany had neutralizing antibodies (Ackermann, 1973) . Of the serum samples of nearly 500 forestry workers from Trentino (Italy) tested by IFA, 12 (2.5%) were positive for specifi c LCMV IgG (Kallio-Kokko et al., 2006) . Immunoprecipitation analysis of 56 human sera in Slovakia revealed 37.5% seropositivity for anti-nucleoprotein (anti-NP) IgG (Reiserová et al., 1999) .
Since there is no commercially available ELISA kit for the detection of LCMV-specifi c antibodies in human sera, we developed a sensitive method using an anti-NP monoclonal antibody and cells persistently infected with the LCM virus. In this paper, we outline this ELISA protocol, determine its clinical sensitivity and specifi city, and describe its application for the detection of LCMV IgG antibody seroprevalence in a group of multiorgan donors in comparison to the immunofl uorescence antibody assay.
Materials and Methods
Cell culture and virus. BHK21 cells were infected with lymphocytic choriomeningitis virus strain MX (designated BHK/ MX) by fi ltered cell free extract as described earlier (van der Zeijst et al., 1983) . Noninfected BHK21 cells cultured in parallel were used as control. Th e cells were grown in Dulbecco modifi ed Eagle medium (DMEM) with 10% FCS, 2 mmol/l L-glutamine, and 160 μg/ml gentamicin and maintained at 37°C in a humidifi ed 5% CO 2 atmosphere.
Collection of samples. Sera samples were collected by MVDr. Ján Rosocha, CSc. from the Faculty of Medicine, Pavol Jozef Šafárik University and Louis Pasteur University Hospital Associated Tis-sue Bank in Košice and by MUDr. Ľuboslav Beňa, PhD. from the Department of Transplantation of the LP UH in Košice, Slovakia. Sera used for the determination of the cut-off value were collected by MUDr. Daniel Kuba, PhD. from the National Transplantation Organization, Slovakia. Anti-LCMV antibody-positive KH serum from a mammary carcinoma patient was described previously (Závada et al., 1972) .
Antibodies. Mouse monoclonal antibodies M16 and M87 detect diff erent epitopes of LCMV NP (Pastorekova et al., 1992; Tomaskova et al., 2011) . M16 was labelled with Alexa Fluor 488 using Molecular Probes' Alexa Fluor® 488 antibody labelling kit (Invitrogen, UK) according to the manufacturer's instructions. Secondary antibodies used were goat anti-human IgG (Fc-specifi c)peroxidase antibody, goat anti-mouse IgG (Fc-specifi c)-peroxidase antibody (both from Sigma, USA) and goat anti-human IgG (H+L)/ Alexa Fluor 568 (Invitrogen).
Determination of nucleoprotein concentration in BHK/MX protein extracts. For protein extraction, BHK/MX and BHK21 cells were lysed in ice-cold lysis buff er (50 mmol/l Tris pH 7.5, 150 mmol/l NaCl, 1% Triton X-100, 0.1% sodium deoxycholate) containing inhibitors of proteases (Roche Applied Science, Germany). Antigen (NP of LCMV) concentration was set indirectly by the ELISA method where 96-well high binding plate (Greiner Bio-One, Austria) was coated with BHK/MX and BHK21 protein extracts. Aft er incubation at 37°C overnight, the plates were washed three times with 0.1% Tween 20 in PBS (Tween-PBS). Th en, each well of the plates was blocked for 1.5 hr with 10% nonfat dry milk in 0.1% Tween 20 in PBS (200 μl per well) and washed 3 times with Tween-PBS. Aft er this step, plates were incubated for 1 hr with purifi ed M87 antibody in blocking buff er at concentration 250 ng/well. Th e plates were then washed and incubated for 1 hr with goat anti-mouse IgG (Fc-specifi c)-peroxidase antibody (Sigma) diluted 1:10,000 in blocking buff er. Peroxidase activity was detected by colorimetric reaction using o-Phenylenediamine, which was stopped by 50 μl of 1 mol/l H 2 SO 4 . Optical density (OD) was measured at 492 nm by the Synergy HT reader (BioTech Instruments, USA). Adjusted optical density was calculated by subtracting the OD of the negative antigen-coated wells and was set as OD NP .
Enzyme-linked immunosorbent assay with human sera. Detection of nucleoprotein specifi c serum antibodies was carried out by sandwich ELISA. To obtain the best signal to noise ratio, diff erent protocols were used. Th e maximum diff erences in optical density values between positive and negative sera were achieved by following this protocol: 96-well high binding plates were coated with NP-specifi c monoclonal antibody M87 at the fi nal concentration of 250 ng per well diluted in 0.05 mol/l sodium carbonate-bicarbonate buff er (pH 9.6). Aft er incubation at 4°C overnight, the plates were washed three times with 0.1% Tween 20 in PBS. Th en, each well of the plates was blocked for 1.5 hr with 200 μl of 10% milk in Tween PBS and washed 3 times. Subsequently, plates were incubated for 1 hr with protein extracts (BHK/MX and BHK21) in blocking buff er. Th e adjusted optical density of nucleoprotein in BHK/MX protein extracts set by the ELISA method described above was 0.36. Th e plates were then washed and incubated with human serum samples diluted 1:40 in PBS in a total volume of 50 μl per well. In the case of determining anti-NP antibody titers, sera were serially diluted in PBS. Each serum was analysed in duplicates. Aft er 1 hr incubation, the plates were washed and subsequently incubated for 45 min with goat anti-human IgG (Fc-specifi c)-peroxidase Ab (Sigma) diluted 1:35,000 in blocking buff er. Peroxidase activity was detected by colorimetric reaction using o-Phenylenediamine, which was stopped by 50 μl of 1 mol/l H 2 SO 4 . Optical density was measured at 492 nm by the Synergy HT reader. Adjusted OD was calculated by subtracting the OD of the negative antigen-coated wells.
Cut-off value determination. To fi nd suitable internal positive and negative controls, human sera were analysed by immunoprecipitation and subsequent immunoblotting with NP-specifi c monoclonal antibody (described below). 25 sera, which had been proved negative with the immunoprecipitation test, were subsequently analysed in ELISA and the adjusted OD values obtained were then expressed as percent positivity (PP) of the average of 5 internal positive controls (selected based on the immunoprecipitation results). PP was calculated as follows: the mean of the adjusted OD value from duplicate samples divided by the mean value of the adjusted OD values of the fi ve positive controls multiplied by 100. Th e ELISA cut-off value, which served as the threshold between positive and negative serum samples, was determined as the mean PP value obtained with these 25 samples plus three standard deviations.
Indirect detection of anti-NP antibodies in human sera by immunoprecipitation. BHK/MX and BHK lysates (200 μg of proteins per sample) were precleared with 60 μl of 50% suspension of Protein G-Sepharose (PGS; GE Healthcare, Sweden). Eight μl of human serum were incubated with 192 μl of 10% FCS in PBS for 1 hr at room temperature. Th e mixture was further added to precleared cell lysates and immunocomplexes were allowed to form on rotating shaker at 4°C overnight. Immunocomplexes were then incubated with 80 μl of 50% suspension of Protein G-Sepharose in PBS for 3 hr at 4°C. Beads were washed six times with PBS, immunoprecipitated proteins were subjected to SDS-PAGE and transferred onto a polyvinylidene difl uoride membrane (Immobilon, Millipore, USA). Membranes were probed with specifi c anti-NP monoclonal antibody M87 in medium, washed with washing buff er (0.2% Nonidet P-40 in PBS), and fi nally incubated with secondary goat antimouse-peroxidase Ab for 1 hr. Aft er an additional washing step, immunoblots were visualised using the ECL detection system.
Indirect immunofl uorescence antibody test. To prepare antigen for the IFA, mixture of BHK/MX and BHK21 (1:1) cells were grown on glass coverslips. Aft er removing the medium and washing with PBS, the cells were fi xed with ice-cold methanol at -20°C for 5 min. Nonspecifi c binding was blocked by incubation with 3% bovine serum albumin (BSA) in PBS for 1 hr at room temperature. Subsequently, the cells were incubated with human serum diluted 1:40 in 1% BSA for 1 hr at room temperature. Aft er washing fi ve times with 0.1% Tween 20 for 5 min, the cells were incubated with anti-human/Alexa Fluor 568 secondary antibody and M16/ Alexa Fluor 488 antibody (diluted 1:1,700 and 1:190 in 1% BSA respectively) for 1 hr at 37°C. Aft er washing, cells were mounted on slides with Fluoroshield mounting medium with DAPI (Abcam, UK) and analysed by confocal microscope LSM 510 META (Zeiss, Germany).
Calculations of clinical sensitivity and specifi city of ELISA and IFA. As already mentioned, there is no commercially available and routinely used ELISA test for the detection of LCMV-specifi c antibodies, which could be considered as a "gold standard". Th erefore we decided to validate our new ELISA test and standard IFA against immunoprecipitation, which in our hands served as the "gold standard" method.
Clinical sensitivity was calculated as: [number of true positive sera/(number of true positive sera+number of false negative sera)]*100%.
Clinical specifi city was calculated as: [number of true negative sera/(number of true negative sera+number of false negative sera)]*100%.
Results

ELISA protocol optimization
To obtain maximum diff erences in the OD values of the positive and negative sera, diff erent ELISA formats and various titration protocols for the antibody and antigen were analysed. Th e best results were achieved when instead of coating the plates with NP containing cell lysate, the monoclonal NP-specifi c Ab M87 was used (Fig. 1a) . To determine the appropriate concentration of purifi ed M87 antibody and NP containing BHK/MX protein extracts pre-
Fig. 1
Development of ELISA (a) ELISA scheme. Wells were coated with monoclonal antibody M87 (specifi c to nucleoprotein (NP) of LCMV). Nucleoprotein present in BHK/ MX cell lysates served as antigen. Anti-nucleoprotein IgG antibodies in human sera were detected by peroxidase-labelled anti-human antibody. (b) Anti-NP IgG-positive human serum KH ELISA results. Th e wells were coated with 250 ng of purifi ed M87 antibody, followed by incubation with BHK/MX protein extracts with ODs corresponding to NP concentrations of 0.21, 0.36 and 0.81. BHK21 and antigen-positive BHK/MX lysate concentrations were equivalent. KH serum was diluted to 1:40 in PBS or in blocking buff er (BB; 10% milk in 0.2% Tween-20 in PBS). Adjusted optical densities were calculated by subtraction of the appropriate unspecifi c background at 492 nm. pared from BHK21 cells persistently infected with LCMV strain MX, we tested four diff erent concentrations of M87 (200, 250, 300, and 350 ng/well) diluted in carbonate-bicarbonate buff er and three concentrations of BHK/MX protein extracts, in which ODs corresponding to the amount of NP (OD NP ) were 0.21, 0.36 and 0.81. Concentrations of BHK21 protein extracts coincided with concentrations of antigen-positive BHK/MX lysates. Positive control human serum KH was diluted in blocking buff er (10% milk in Tween-PBS) or in PBS and tested in duplicate for each Ab-Ag combination. Comparison of blocking buff ers (10% milk in 0.1% Tween 20 in PBS and 10% FCS in Tween-PBS) showed that 10% milk was as eff ective as 10% FCS. Analysis of anti-human-peroxidase secondary antibody incubation times proved that shortened incubation (45 min instead of 1 hr) led to reduced background signal. Th e adjusted OD was calculated by subtracting the OD of the BHK21protein extract-coated wells from that of the corresponding BHK/MX wells. Th e observed optical densities (Fig. 1b) showed that the best signal to noise ratio was provided with OD NP = 0.36 and serum diluted in PBS. Since diff erences between M87 concentrations did not signifi cantly alter the results (data not shown), we decided to use 250 ng of antibody per well in the subsequent assays.
Determination of cut-off value
To diff erentiate between positive and negative sera in ELISA, we had to determine the cut-off value of absorbance. For this purpose we decided to use another anti-NP IgG antibody detecting method -immunoprecipitation. IgG antibodies in human sera (8 μl) were bound to protein G and aft er incubation with NP-containing BHK/MX lysate, nucleoprotein was detected by Western blot using specifi c monoclonal antibody M87. We thus indirectly confi rmed the presence of anti-NP IgGs in the sera. Based on the immunoprecipitation results (Fig. 2) , we selected 25 negative and 5 positive sera, which we used for the determination of the ELISA cut-off value that served as the threshold between positive and negative serum samples. Th e OD average value which resulted from ELISA testing of negative sera was 0.009. Th e average of adjusted ODs of 5 internal positive controls was 1.028. Subsequently, values were changed to percent positivity (PP). Th e cut-off value was determined as the mean percent positivity obtained with 25 negative samples plus three standard deviations. Using this method, the cut-off value was determined to be 4.28%, which represents OD at 0.044 and was used for subsequent ELISA analyses.
Moreover, we titrated all 5 sera, which were used as positive controls in the cut-off determination and found that anti-NP IgG titers in these sera were 800, 1,600, 5,000, 10,000, and 15,000. Immunoprecipitation with human sera BHK/MX (B/X) and BHK21 (B) cell lysates were incubated with human sera, followed by the binding of the immunocomplexes to Protein G-Sepharose (PGS). Subsequently, the presence of anti-NP IgG antibodies was detected with anti-NP monoclonal antibody M87 by Western blot. Cell lysates incubated with anti-NP monoclonal antibody M16 and PGS and cell lysates incubated only with PGS served as controls. Using this method, we were able to diff erentiate positive (strongly positive serum +++, weakly positive serum +) and negative (-) sera.
Fig. 3
Testing of 45 sera by ELISA, IFA and "gold standard" immunoprecipitation Human sera (diluted 1:40 in PBS) were tested by the developed ELISA, standard IFA and 8 μl of each serum were analysed also by immunoprecipitation (IP). Th reshold OD value for ELISA was 0.044. Th e results were used for clinical specifi city and sensitivity calculations of the ELISA and IFA methods (Table 1) . 
Determination of clinical ELISA sensitivity and specificity and comparison with IFA
Aft er optimization of the ELISA method, we determined its clinical sensitivity and specifi city. For this purpose, 25 negative and 20 positive sera (based on the immunoprecipitation results) were tested by a new ELISA test. To compare the developed ELISA to another standard method, we analysed the same sera with IFA ( Fig. 3 ). As shown in Table 1 , clinical sensitivity of our ELISA is 75%, since we were able to detect 15 positive sera out of 20 and clinical specifi city is 100%, since we detected as negative all sera, which were Indirect immunofl uorescence assay with human sera Mixture of BHK21 cells and BHK21 cells persistently infected with LCMV strain MX was incubated with human sera diluted to 1:40. Anti-LCMV IgG antibodies were visualised by anti-human Ab labelled with Alexa Fluor 568 (red). To simultaneously identify cells infected with the virus, nucleoprotein was detected by monoclonal antibody M16 labelled with Alexa Fluor 488 (green). 
Fig. 5
Testing of multiorgan donor sera 30 sera were analysed by the newly-established ELISA and standard IFA. Th reshold OD value for ELISA was 0.044. Results were used for the calculation of the total coincidence rate of the two tests. found to be negative by immunoprecipitation. On the other hand, clinical sensitivity of IFA is 45% (we detected 9 sera as positive out of 20) and specifi city is 100%.
Testing of multiorgan donor sera
Furthermore, we used our ELISA for the detection of anti-NP antibodies in 30 sera collected from multiorgan donors. Based on the obtained adjusted OD values, calculated percent positivity, and comparison to the cut-off value, we designated 2 sera as positive and 28 as negative. Positive sera were subsequently titrated and the antibody titer of a strongly positive serum was estimated 1,600 and of a weakly positive serum 40.
Th e same sera were then analysed with IFA. Representative samples of IFA, including the positive serum KH (Fig. 4a ) are shown in Fig. 4 . Only 1 out of 30 clinical samples was found positive using the IFA method (Fig. 4b) . One weakly positive serum in ELISA (anti-NP IgG titer 40) was negative in IFA ( Fig. 4c) . Comparison of the ELISA to the IFA results showed a total coincidence rate of 96.67% ( Fig. 5 ; Table 2 ).
Discussion
Lymphocytic choriomeningitis virus is a human pathogen, which, as has been recently shown, possesses a great risk to several groups of people. Congenital infection may lead to spontaneous abortion (Bonthius et al., 2007) , and previously documented cases of transplant-associated infections of immunocompromised individuals showed fatal outcomes in most patients (Fischer et al., 2006; CDC, 2008; Palacios et al., 2008; MacNeil et al., 2012; Schafer et al., 2014) . In the case of congenital infection, the virus may not be detected aft er the infant is born, but specifi c IgGs are present in the mother's and infant's sera. Th e most common methods for the detection of specifi c anti-LCMV antibodies in sera are ELISA and IFA (OIE, 2006) . Th e complement fi xation test is relatively insensitive. Since there are no commercial ELISA kits for the detection of such antibodies available for routine use, we developed a method serving this purpose. For the ELISA tests, the antigen is usually prepared from cells infected with LCMV (Marrie and Saron, 1998; Riera et al., 2005) . During such preparation of the antigen, handling of infectious LCMV is required, which is necessary to perform in a biosafety containment facility. In our ELISA, we used nucleoprotein-containing protein extracts from MXinfected BHK21 cells as antigen. Th e advantage of the LCMV strain MX is that it causes persistent infection of cells, and therefore provides cell lysates containing large amounts of antigen. Moreover, it does not form distinct virions released into the medium, and its transmission to uninfected cells in normoxia is mediated only by direct cell-cell contact (Reiserová et al., 1999; Laposova et al., 2013) . Th is makes the handling of MX (and MX-infected cells) safer than handling other strains of LCMV. Also, ELISA with recombinant LCMV-NP as antigen has been previously reported by several groups (Homberger et al., 1995; Takimoto et al., 2008) . In this case, either crude extracts from insect cells infected with recombinant baculovirus (Homberger et al., 1995) or LCMV-NP obtained by purifi cation with high molar urea were used as antigen (Takimoto et al., 2008) . According to published data, the ELISA assay using purifi ed antigen was more sensitive in the detection of anti-LCMV antibodies. In our assay, we used an NP-capturing monoclonal antibody for the purifi cation of LCMV-NP directly in the multiwell plate. Preparation of antigen by this method is more convenient and less time consuming in comparison to preparation of purifi ed recombinant LCMV-NP. Th e use of the monoclonal anti-NP antibody in the fi rst step also increases ELISA specifi city and leads to a reduced background signal. By our ELISA assay, we detect specifi c anti-NP antibodies in acute, as well as persistent infection because nucleoprotein is highly produced in both, in contrast to the viral glycoprotein, the production of which is limited in the persistent state (Francis and Southern, 1988) . To distinguish positive and negative sera, we had to set a cut-off value. According to literature, there are many methods for determination of the ELISA threshold. We decided to use calculations based on the results of immunoprecipitation, since it is a very sensitive method, and it allowed us to identify anti-NP antibody-positive and -negative sera by Western blot. Subsequently, the sera were tested by ELISA, and their absorbances were used for the cut-off value calculation where we set stringent conditions to avoid false positive results. Aft er determining the threshold, we calculated clinical sensitivity and specifi city of the newly-developed ELISA and standard IFA. Results show, that clinical specifi city of both methods is 100%, but clinical sensitivity of ELISA is 30% higher than that of IFA. Next, we analysed sera from multiorgan donors since this is an interesting group of samples based on the recently described LCMV transmission through organ transplants (Fischer et al., 2006; CDC, 2008; Palacios et al., 2008; MacNeil et al., 2012; Schafer et al., 2014) . We identifi ed 2 of those sera as positive by our new ELISA method. Comparison of these results to the IFA method showed that the newly-established ELISA is more sensitive, since a weakly positive serum detected by ELISA (titer of anti-NP IgG 40) was negative by IFA. With this method, we were able to detect only the serum with anti-NP IgG titer 1,600. Moreover, in our experience, the testing of human sera by the IFA method is accompanied by high background, which is signifi cantly reduced in ELISA.
In summary, our ELISA assay is very sensitive and enables the detection of NP-specifi c antibodies, which can be used not only for determining the prevalence of LCMV-specifi c antibodies in human populations for scientifi c purposes, but also for the diagnostic testing of LCMV infection.
